KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 18282 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
IV Fosphenytoin for Acute Trigeminal Neuralgia: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. PMID 42096672 · Neurology · 2026-Jun-09 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Comparative Efficacy of First-Line Therapeutic Options for ES-SCLC: An Indirect Comparison Using IPDfromKM-Reconstructed Individual Patient Data. PMID 42352404 · Cancers (Basel) · 2026-Jun-08 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
The Efficacy of Dexamethasone Versus N-Acetylcysteine in Prevention of Post-Embolization Syndrome in Hepatocellular Carcinoma Patients: A Multicenter Randomized, Double-Blind, Double-Dummy, Non-Inferiority Trial. PMID 42260068 · Asia Pac J Clin Oncol · 2026-Jun-08 The study is a randomized Phase 3 oncology trial with drug intervention, but its primary endpoint is the incidence of post-embolization syndrome (a complication/safety outcome) at 48 hours, not a time-to-event efficacy endpoint (e.g., OS, PFS, DFS). Therefore, it does not meet the core criterion for inclusion in a Kaplan-Meier digitization cohort.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and Safety Profile of a Triple Single-Pill Combination of Valsartan/Amlodipine/Chlorthalidone in Patients with Uncontrolled Hypertension. PMID 42259717 · Clin Ther · 2026-Jun-08 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Histologic and combined histologic-endoscopic outcomes with mirikizumab in Crohn's disease: VIVID-1 trial results. PMID 42309525 · J Crohns Colitis · 2026-Jun-07 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Final Analysis of Neoadjuvant Sintilimab Plus Chemotherapy in IB-IIIA Non-Small-Cell Lung Cancer: Phase 2 neoSCORE Trial. PMID 42252705 · Cancer Sci · 2026-Jun-07 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Dose-Response and Clinical Equivalence of Semaglutide and Tirzepatide for Weight Loss in Type 2 Diabetes: A Model-Based Analysis. PMID 42252377 · Diabetes Ther · 2026-Jun-07 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial. PMID 42252333 · Nat Med · 2026-Jun-07 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study. PMID 42251859 · Lancet Diabetes Endocrinol · 2026-Jun-07 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Orforglipron Added to Titrated Insulin Glargine in Type 2 Diabetes: The ACHIEVE-5 Randomized Clinical Trial. PMID 42251769 · JAMA · 2026-Jun-07 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial. PMID 42251595 · JAMA · 2026-Jun-07 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Comment on "Clazakizumab in the treatment of chronic active antibody-mediated kidney transplant rejection: Results from the IMAGINE phase 3, randomized, double-blind, placebo-controlled study". PMID 42252027 · Am J Transplant · 2026-Jun-06 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Impact of Mavacamten on Disease-Related Symptoms in Patients With Obstructive Hypertrophic Cardiomyopathy: HCMSQ Outcomes in EXPLORER-HCM. PMID 42251960 · J Card Fail · 2026-Jun-06 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Comparison of erector spinae plane, paravertebral, and pectoral nerve blocks on postoperative analgesia and Quality of Recovery-15 in patients undergoing mastectomy: a prospective randomized trial. PMID 42251440 · Perioper Med (Lond) · 2026-Jun-06 Study is a randomized trial in an oncology (breast cancer surgery) setting and reports a time-to-event endpoint. However, it is excluded because the intervention consists of regional anesthesia techniques (nerve blocks) and not a systemic or targeted drug therapy for treatment efficacy. The primary endpoint is total morphine consumption (a safety/analgesic endpoint), not a standard efficacy endpoint like OS/PFS.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Early antiretroviral therapy and long-term cancer risk in HIV: 9-year outcomes from the START randomized trial. PMID 42251304 · BMC Cancer · 2026-Jun-06 The study is a well-conducted randomized trial with a drug intervention and time-to-event endpoint, but it does not meet the strict eligibility criteria because: 1) The phase of the trial is not explicitly established as Phase III/IIIb or Phase II/III in the provided abstract (though the START trial is a definitive trial, the phase is not stated here), and 2) This specific analysis is a long-term follow-up/secondary analysis of cancer outcomes rather than the primary trial result report. Therefore, it is excluded.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Phase III maintenance telerehabilitation in elderly patients with chronic heart failure and type 2 diabetes (TELEMECHRON study). PMID 42250988 · Eur J Intern Med · 2026-Jun-06 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and safety of the CD40 ligand inhibitor dapirolizumab pegol in systemic lupus erythematosus (PHOENYCS GO): a randomised, double-blind, placebo-controlled, phase 3 trial. PMID 42214397 · Lancet · 2026-Jun-06 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: a randomized phase 3 study. PMID 42179186 · Oncologist · 2026-Jun-06 The study is a randomized Phase III trial of a drug combination in oncology with original results. However, the primary and key secondary endpoints are response rates (SVR and TSS reduction), which are categorical outcomes, not time-to-event endpoints (OS, PFS, DFS, EFS, RFS, TTP, or survival analysis with Kaplan-Meier or HR). Therefore, it does not meet the time-to-event efficacy criterion for this cohort.
H L
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial. PMID 42119587 · Lancet · 2026-Jun-06 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Survival benefit of oral systemic monotherapy in previously treated metastatic colorectal cancer: a meta-analysis. PMID 42104118 · Oncologist · 2026-Jun-06 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Impact of Availability of Computer-Aided Detection Devices on Adenoma Detection During Colonoscopy: A Cluster Randomized Study. PMID 42250891 · Gastroenterology · 2026-Jun-05 Study is a cluster randomized pragmatic quality improvement study assessing the impact of a computer-aided detection device on adenoma detection rates during colonoscopy. While oncology-related, it lacks a drug intervention, is not a Phase III or Phase II/III trial, and does not report a primary time-to-event efficacy endpoint like OS, PFS, DFS, etc. Adenoma detection rate is an intermediate surrogate endpoint, not a time-to-event outcome.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Integrating multiple outcomes of first-line immunotherapy-based regimens for advanced hepatocellular carcinoma: A network meta-analysis of phase III trials. PMID 42250662 · Crit Rev Oncol Hematol · 2026-Jun-05 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Multimodal Artificial Intelligence Prediction of Abiraterone Efficacy in Two STAMPEDE Phase 3 Trials of Non-Metastatic Very High-Risk Prostate Cancer. PMID 42250604 · Ann Oncol · 2026-Jun-05 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
A randomized double-blind placebo-controlled phase I/II clinical trial of a human papillomavirus therapeutic vaccine, PepCan, for reducing head and neck squamous cell carcinoma recurrence. PMID 42249801 · Oncotarget · 2026-Jun-05 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Efficacy and safety of fibrinogen concentrate (BT524) in severe hemorrhage: Phase 3 subcohort analysis of the AdFIrst trial in patients undergoing cytoreductive surgery for pseudomyxoma peritonei. PMID 42247815 · J Clin Anesth · 2026-Jun-05 未发现恶性肿瘤人群证据。
H L B
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Levofloxacin/ketorolac combination versus levofloxacin alone for topically treating moderate-severe acute bacterial conjunctivitis: a randomized controlled trial. PMID 42247155 · Graefes Arch Clin Exp Ophthalmol · 2026-Jun-05 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Obinutuzumab or Tacrolimus in Primary Membranous Nephropathy. PMID 42246654 · N Engl J Med · 2026-Jun-05 The record describes a Phase III randomized trial of obinutuzumab in primary membranous nephropathy, which is not an oncology condition. The primary efficacy endpoint is complete remission at week 104 (a categorical endpoint), not a time-to-event endpoint like OS, PFS, or DFS. Therefore, it does not meet the core eligibility criteria for inclusion in an oncology Kaplan-Meier digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Finerenone in Patients With Chronic Kidney Disease Due to Glomerular Diseases: A Randomized Clinical Trial. PMID 42246414 · JAMA · 2026-Jun-05 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
The Efficacy and Safety of Etrasimod in Mildly to Moderately Active Ulcerative Colitis: Results From the Phase II GLADIATOR Trial. PMID 42248437 · Clin Gastroenterol Hepatol · 2026-Jun-04 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Community health worker implementation of transdiagnostic evidence-based treatment in Spanish: protocol for refinement, implementation, and a feasibility pilot RCT. PMID 42243988 · Implement Sci Commun · 2026-Jun-04 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Reduced/No Dexamethasone With Netupitant/Palonosetron and Olanzapine for Chemotherapy‑Induced Nausea/Vomiting in Highly Emetogenic Chemotherapy: Phase III Noninferiority Trial. PMID 42241642 · J Clin Oncol · 2026-Jun-04 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
First-Line Serplulimab in Extensive-Stage Small Cell Lung Cancer: Secondary Analysis of the ASTRUM-005 Phase 3 Randomized Clinical Trial. PMID 42240984 · JAMA Oncol · 2026-Jun-04 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Robustness of placebo-controlled trials of extended-duration direct oral anticoagulant therapy for secondary venous thromboembolism prevention. PMID 42240800 · Intern Emerg Med · 2026-Jun-04 The record describes a systematic review of randomized phase 3/4 trials of direct oral anticoagulants (DOACs) for secondary prevention of venous thromboembolism (VTE) in non-cancer patients. The primary endpoint is symptomatic recurrent VTE, which is not an oncology time-to-event efficacy endpoint (OS, PFS, DFS, etc.). The study population is non-cancer, and the disease is not a human malignant neoplasm. Therefore, it is excluded based on non-oncology.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Early vs. delayed primary local therapy and survival in de novo metastatic prostate cancer: target trial emulation. PMID 42240667 · World J Urol · 2026-Jun-04 The record describes an observational target trial emulation of a non-drug intervention (primary-directed local therapy) for metastatic prostate cancer. It is not a randomized trial, and it does not involve a drug-containing intervention as defined by the criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Immunogenicity and safety of co-administration of AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine and a COVID-19 mRNA vaccine in adults aged ≥50 years: a phase 3, randomized, non-inferiority trial. PMID 42240564 · Clin Infect Dis · 2026-Jun-04 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Immune checkpoint therapy in pediatric and adolescent lymphomas. PMID 42237783 · Haematologica · 2026-Jun-04 The record describes a Phase III randomized trial but does not report any time-to-event efficacy results (e.g., OS, PFS, Kaplan-Meier curves, HR). It is a protocol/conference abstract noting expected results in 2027, not an original result report of efficacy.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Long-Term Survival Outcomes of Immune Checkpoint Inhibitor-based Combination Therapies in Favorable-Risk Metastatic Renal Cell Carcinoma: An Updated Pairwise and Network Meta-Analysis. PMID 42350220 · Clin Genitourin Cancer · 2026-Jun-03 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Safety of remibrutinib in chronic spontaneous urticaria: a pooled analysis of REMIX-1 and REMIX-2 trials. PMID 42242425 · J Allergy Clin Immunol Pract · 2026-Jun-03 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
JAAD Game Changers: A novel lotion formulation of 20% oxybutynin hydrochloride for the treatment of primary palmar hyperhidrosis: a randomized, placebo-controlled, double-blind, phase III study. PMID 42242363 · J Am Acad Dermatol · 2026-Jun-03 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Mesenchymal stromal cell infusions of umbilical cord-derived mesenchymal stromal cells in children with Recessive Dystrophic Epidermolysis Bullosa (MissionEB): a qualitative sub study of a randomised, double-blind, placebo controlled, crossover, phase 3 trial. PMID 42237200 · Orphanet J Rare Dis · 2026-Jun-03 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Clinical efficacy and safety of aflibercept biosimilars in neovascular age-related macular degeneration: a systematic review and meta-analysis of randomised controlled trials. PMID 42236129 · Br J Ophthalmol · 2026-Jun-03 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Incidence and treatment-modifying impact of immune checkpoint inhibitor-associated peripheral edema: a systematic review and meta-analysis. PMID 42234870 · JNCI Cancer Spectr · 2026-Jun-03 The record is a systematic review and meta-analysis of Phase 3 RCTs, not an original primary report of a single trial. It reports safety incidence (peripheral edema) and does not include a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Safety of low lipoprotein(a) levels: the FOURIER trial. PMID 42234492 · Eur Heart J · 2026-Jun-03 This is a secondary safety analysis from a cardiovascular outcomes trial (FOURIER), not a primary report of oncology efficacy. The study is not oncology-focused, and while it includes malignancy as a safety outcome, malignancy is not the primary or key secondary efficacy endpoint. Therefore, it does not meet the inclusion criteria for an oncology Kaplan-Meier digitization cohort focused on drug intervention efficacy.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Old and New Lines of Therapy Targeting Lipoprotein(a). PMID 42234287 · Curr Atheroscler Rep · 2026-Jun-03 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Clinical effectiveness of efgartigimod in a broad population of patients with generalized myasthenia gravis: subgroup analyses from a randomized, double‑blind, placebo‑controlled, phase 3 trial (ADAPT). PMID 42234197 · J Neurol · 2026-Jun-03 未发现恶性肿瘤人群证据。
H L B
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
STS101 nasal powder as a new treatment option for acute migraine with or without aura in adults. PMID 42217235 · Expert Rev Neurother · 2026-Jun-03 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Prostate cancer mortality among men with and without comorbidity: Long-term results from the European randomized study of screening for prostate cancer Rotterdam. PMID 41997039 · Eur J Cancer · 2026-Jun-03 The record is a randomized trial with a time-to-event oncology endpoint (prostate cancer mortality) and reports original results. However, it fails the drug-intervention criterion because the intervention is PSA screening, not a drug. Therefore, it is not eligible.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Laparoscopic versus open pancreaticoduodenectomy in patients with periampullary carcinoma: A randomised clinical trial. PMID 42262773 · J Minim Access Surg · 2026-Jun-02 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Obexelimab for the Treatment of IgG4-Related Disease. PMID 42233621 · N Engl J Med · 2026-Jun-02 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Long-term effect of sweeteners and sweetness enhancers on gene expression markers of adipose tissue function, adipocyte morphology, and metabolic health: a SWEET substudy. PMID 42230988 · Int J Obes (Lond) · 2026-Jun-02 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -